Wellington Management Group LLP Has $219,000 Stake in Halozyme Therapeutics, Inc. $HALO

Wellington Management Group LLP reduced its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 72.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,794 shares of the biopharmaceutical company’s stock after selling 7,494 shares during the period. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $219,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Archer Investment Corp bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter valued at about $78,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $9,710,000. Orion Capital Management LLC bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $337,000. Empowered Funds LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $6,880,000. Finally, United Capital Financial Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter worth approximately $1,070,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HALO has been the topic of several analyst reports. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. TD Cowen boosted their price target on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. HC Wainwright restated a “buy” rating and issued a $115.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Finally, Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Trading Up 0.2%

NASDAQ HALO opened at $107.20 on Friday. The business has a 50 day simple moving average of $93.73 and a 200 day simple moving average of $76.97. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $111.15. The stock has a market capitalization of $12.17 billion, a P/E ratio of 32.00, a P/E/G ratio of 0.41 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The business had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same period in the previous year, the company posted $1.54 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Research analysts expect that Halozyme Therapeutics, Inc. will post 8.25 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company’s stock, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $107.24, for a total transaction of $2,144,800.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $82,336,727.20. The trade was a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,478 shares of company stock valued at $7,370,004 in the last quarter. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.